Intersect ENT®, Inc. (Nasdaq:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) for a new Straight Delivery System (SDS) for use to place its PROPEL® Mini steroid releasing sinus implant in the ethmoid sinus.
July 25, 2019
· 4 min read